萬基遺傳 MYGN 深 滬
等待開盤 09-08 09:30:00 美东时间
3.19
-0.040
-1.24%
華盛通- 最 高3.20
- 今 開3.19
- 成交量 80.60万股
- 最 低 3.15
- 昨 收 3.23
- 總市值 3.05亿
- 52周最高 8.59
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 2.74
- 委 比 -48.31%
- 總股本 9564.96万
- 歷史最高 50.44
- 量 比 0.48
- 振 幅 1.55%
- 歷史最低 2.74
- 每 手 1
- 風險率 1.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cango, Nio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Cango Inc (NYSE:CANG) fell sharply in pre-market trading as the company posted downbeat results for the second quarter. Cango reported quarterly losses of $1.99 per share which missed the...
09-01 20:02
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
<p>Myriad Genetics, Inc. will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on September 10, 2026. The presentation will be available via a live audio webcast on Myriad’s investor website. Myriad Genetics is a leading molecular diagnostic and precision medicine company focused on improving patient care through genetic insights. For more information, visit their website or contact investor and media relations.</p>
08-27 13:05
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.
08-18 22:03
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoi...
08-10 22:07
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company lowered its FY2026 sales guidance below estimates.
Myriad Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, the company lowered its FY2026 sales guidance below estimates.
07-31 04:49
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
Myriad Genetics will hold its second quarter 2026 earnings conference call on July 30, 2026, at 4:30 pm ET. The company will release its quarterly earnings the same day after market close. Management will discuss financial results and business updates during the call. A live webcast and archived recording will be available on investor.myriad.com. Participants can register for the call via the provided link. Myriad Genetics is a leader in molecula...
07-23 13:05
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics announces that the Prolaris Biopsy Test provides significant prognostic information beyond conventional clinical risk categories for localized prostate cancer, as shown in a meta-analysis of 14 studies involving over 8,000 patients. The Prolaris combined clinical risk score (CCR) is prognostic for distant metastasis and prostate cancer-specific mortality across all risk groups, offering independent, additive prognostic value beyon...
07-02 13:05
